

Yngvild Olsen, M.D., M.P.H.

Phone: [REDACTED]

Email: [REDACTED]

EMPLOYMENT

Manatt Health Services

July 2025-present

National Advisor

I provide policy and practice-oriented, strategic technical assistance to states, non-profit organizations, and companies on a wide range of substance use disorder-related topics.

Substance Abuse and Mental Health Services Administration

September 2021-July 2025

Center for Substance Abuse Treatment

Director (as of April 2022)

I oversaw the Center that promotes policies to expand access to care, promulgates evidence-based practice, supports workforce development, and provides close to \$5 billion in grant funds to States, territories, Tribes, and community-based organizations to support the continuum of care and services for people with substance use disorders.

Institutes for Behavior Resources, Inc./REACH Health Services

Medical Director

Nov 2011 – September 2021

Physician

September 2021-present

As Medical Director, in addition to providing direct patient care, I led clinical policy development for the clinic, oversaw and directed medical staff, and assisted senior leadership with strategic planning and service development. Upon accepting a position at SAMHSA in September 2021, I resigned my position as Medical Director but maintained a role as physician. In that role, I provide direct patient care for individuals with opioid use disorder and other health conditions.

Consultative Services

Nov 2011 – September 2021

Consultant

I developed, led, and conducted a variety of projects focused on opioid overdose prevention, and integrating and improving substance use, mental health, and primary care services. This included consulting for the Behavioral Health Systems Baltimore, Inc, the Maryland Behavioral Health Administration, and Pew Charitable Trust.

Baltimore Substance Abuse System, Inc.

Nov 2009-2011

Medical Director and Vice President for Clinical Affairs

I formulated and led implementation of clinical programs, practice policies, and standards for city-wide addiction prevention, treatment, and recovery services. In addition, I provided

senior leadership in policy development and strategic planning for an organization with a \$50 million annual budget.

Harford County Health Department

March 2007-2009

Deputy Health Officer and Medical Director

As a state public health official, I oversaw the public substance use treatment system in Harford County, which included both direct treatment services and an external grant program. In this capacity, I worked closely with the local Alcohol and Drug Abuse Council and the Maryland Alcohol and Drug Abuse Administration. I also directed the county's efforts on family planning and control of tuberculosis and other communicable diseases. Beginning in January 2008, I served as the acting deputy health officer (promoted to deputy health officer in July 2009). In this position, I was involved in all aspects of running the health department, which had a \$16 million annual budget.

Johns Hopkins School of Medicine

July 2004-March 2007

Assistant Professor of Medicine

Medical Director for Outpatient Substance Abuse Services

I served as medical director for an opioid treatment program utilizing methadone, buprenorphine, and multiple ASAM levels of care. I served as medical director for a comprehensive day treatment program for medically complex patients with substance use disorders. Working with the Departments of Medicine and Psychiatry, I created the hospital's inpatient substance use liaison service. I participated in substance use-related research and teaching.

EDUCATION

Johns Hopkins School of Medicine

Fellowship, General Internal Medicine, 2001 - 2004

Johns Hopkins Bloomberg School of Public Health

M.P.H., 2002

Boston University School of Medicine

Chief Residency in Primary Care Internal Medicine, 2000 - 2001

Internship and residency training in Internal Medicine, 1997 - 2000

Harvard Medical School

M.D., magna cum laude, 1997

Haverford College

B.S. in Biology with high honors, 1991

AWARDS

Friend of NASADAD Award 2025

National Association of State Alcohol and Drug Agency Directors (NASADAD)
For significant contributions to the field of addiction and substance use.

Keeper of the Flame Award 2025

American College of Academic Addiction Medicine (ACAAM)
For significant contributions to the field of addiction medicine

The John P. McGovern Award 2025

American Society of Addiction Medicine (ASAM)
For highly meritorious contributions to public policy, research, and prevention which has increased understanding of the relationship between addiction and society

The R. Brinkley Smithers Distinguished Scientist Award 2024

American Society of Addiction Medicine (ASAM)
For highly meritorious contributions in advancing the scientific understanding of addiction, its prevention and treatment

The Henrick J. Harwood & Robert E. Anderson Service Award 2020

National Association of State Alcohol and Drug Abuse Directors (NASADAD)
For distinguished service in the field of addiction research, training, and evaluation

Nyswander/Dole "Marie" Award 2015

American Association for the Treatment of Opioid Dependence
For outstanding contributions to opioid treatment

PROFESSIONAL ACTIVITIES

American Society of Addiction Medicine 2004-present

Board Member, At-Large, April 2015 to April 2017

Chair, Public Policy Committee, Aug 2015 to April 2017

Secretary, April 2017 to April 2019

Vice President, April 2019 to April 2021

Chair, COVID-19 Clinical Guidance Task Force, April 2020 to April 2021

Chair, Legislative Advocacy Committee, April 2021 to Sept 2023

Member, Terminology and Definitions Subcommittee, Jan 2021 to Sept 2021

Member, 2004 to present

Maryland Society for Addiction Medicine 2004-present

President 2014-2015

Immediate Past President 2016-2017

Board Member, At-Large 2017-2021

Member, 2004 to present

State chapter of the national American Society of Addiction Medicine

Committee on the Review of Specific Programs in the Comprehensive Addiction and Recovery Act Dec 2018-Sept 2021

National Academies of Sciences, Engineering, and Medicine

Consensus Study Committee Member

National Council on Alcoholism and Drug Dependence-MD 2013-2021

Member, Board of Directors for the state chapter of the National Council on Alcoholism and Drug Dependence, an advocacy organization for recovery

Providers' Clinical Support System for Medication Assisted Treatment 2014-2021

Clinical Expert representing the American Society of Addiction Medicine in a national training and mentoring consortium

Medical Society of Maryland (MedChi) 2014 - 2021

Co-Chair, Addictions Committee

Chair, Opioid Committee, April 2021 to September 2021

Maryland Association for the Treatment of Opioid Dependence 2012-2016

President 2012-2015

Immediate Past President 2015 - 2016

State chapter of the American Association for the Treatment of Opioid Dependence

Maryland Alcohol and Drug Abuse Administration **2007-2009**
Member, Recovery Workgroup that developed plan to transform the publicly funded substance use service system in Maryland to a recovery-oriented model of care.

Medical Licensure and Board Certification

Massachusetts Medical License 1997-2001
Maryland Medical License 2001-present
Board Certification in Internal Medicine 2001, currently Board Eligible
Board Certification in Addiction Medicine, American Board of Preventive Medicine 2022
American Society of Addiction Medicine 2004
American Board of Addiction Medicine 2009, recertification 2014
Drug Enforcement Administration Buprenorphine Waiver 2004 - 2023

Professional Memberships

Member, American College of Physicians
Member and Distinguished Fellow, American Society of Addiction Medicine
Member, Association for Medical Education and Research in Substance Abuse

PEER-REVIEWED SCIENTIFIC PUBLICATIONS

1. Li C, **Olsen Y**, Kvigne V, Welty T. Implementation of Substance Use Screening in Prenatal Clinics. *South Dakota Journal of Medicine* 1999;52:59-64.
2. **Olsen Y**, Alford D, Horton N, Saitz, R. Addressing Smoking Cessation in Methadone Programs. *Journal of Addictive Diseases* 2005;24:33-48.
3. **Olsen Y**, Daumit G, Ford DE. Opioid Prescriptions by U.S. Primary Care Physicians from 1992 to 2001. *Journal of Pain* 2006;7(4):225-235.
4. Becker WC, Fiellin DA, Merrill JO, Schulman B, Finkelstein R, **Olsen Y**, Busch SH. Opioid use disorder in the United States: Insurance status and treatment access. *Drug Alcohol Depend* 2008;Jan 24 (epub).
5. Winstanley EL, Steinwachs DM, Ensminger ME, Latkin CA, Stitzer ML, **Olsen Y**. The association of self-reported neighborhood disorganization and social capital with adolescent alcohol and drug use, dependence, and access to treatment. *Drug Alcohol Depend* 2008;92(1-3):173-82.
6. Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, **Olsen Y**, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD. Clinic-Based Treatment of Opioid-Dependent HIV-Infected Patients Versus Referral to an Opioid Treatment Program. *Ann Int Med* 2010;152(11):704-11.
7. Mitchell SG, Kelly SM, Gryczynski J, Myers CJ, Jaffe JH, O'Grady KE, **Olsen YK**, Schwartz RP. African-American patients seeking treatment in the public sector: Characteristics of buprenorphine *vs* methadone patients. *Drug Alcohol Depend* 2012;122:55-60.

8. Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, **Olsen YK**, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. *Drug Alcohol Depend* 2013;128:222-229.
9. Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsu N, Monroe CL, O'Grady KE, **Olsen YK**, Mitchell SG. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. *Am J Addict*. 2013 May-Jun;22(3):285-91.
10. Schwartz RP, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, **Olsen Y**, Mitchell SG, Jaffe JH. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013 May;103(5):917-22.
11. Gryczynski J, Mitchell SG, Jaffe JH, Kelly SM, Myers CP, O'Grady KE, **Olsen YK**, Schwartz RP. Retention in methadone and buprenorphine treatment among African Americans. *J Subst Abuse Treat*. 2013 Sep;45(3):287-92.
12. Knowlton A, Weir B, Hazzard F, **Olsen Y**, McWilliams J, Fields J, Gaasch W. EMS runs for suspected opioid overdose: Implications for surveillance and intervention. *Prehospital Emergency Care*. 2013;17(3):317-29.
13. **Olsen Y**, Sharfstein JM. Confronting the Stigma of Opioid Use Disorder – and Its Treatment. *JAMA*. 2014 April 9;311(14):1393-4.
14. Mitchell SG, Gryczynski J, Kelly SM, O'Grady KE, Jaffe JH, **Olsen YK**, Schwartz RP. Treatment Outcomes of African American Buprenorphine Patients by Parole and Probation Status. *J Drug Issues*. 2014 Jan;44(1):69-82.
15. Gryczynski J, Mitchell SG, Jaffe JH, O'Grady KE, **Olsen YK**, Schwartz RP. Leaving buprenorphine treatment: patients' reasons for cessation of care. *J Subst Abuse Treat*. 2014 Mar;46(3):356-61.
16. **Olsen Y**, Sharfstein JM. Chronic Pain, Addiction, and Zohydro. *NEJM*. 2014;370:2061-2063.
17. Monico LB, Mitchell SG, Gryczynski J, Schwartz RP, O'Grady KE, **Olsen YK**, Jaffe JH. Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention. *J Subst Abuse Treat*. 2015;57:57-62.
18. Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O'Grady KE, **Olsen YK**, Jaffe JH. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. *J Psychoactive Drugs*. 2015;47(2):149-57.
19. **Olsen Y**. The CDC Guideline on Opioid Prescribing: Rising to the Challenge. *JAMA*. 2016;315(15):1577-1579.
20. Doyon S, Benton C, Anderson BA, Baier M, Haas E, Hadley L, Maehr J, Rebbert-Franklin K, **Olsen Y**, Welsh C. Incorporation of poison center services in a state-

- wide overdose education and naloxone distribution program. *Am J Addict*. 2016;25(4):301-6.
21. Schwartz RP, Kelly SM, Mitchell SG, Gryczynski J, O'Grady KE, Gandhi D, **Olsen Y**, Jaffe JH. Patient-centered methadone treatment: a randomized clinical trial. *Addiction*. 2017;112(3):454-464.
 22. Falade-Nwulia O, Irvin R, Merkow A, Sulkowski M, Niculescu A, **Olsen Y**, Stoller K, Thomas DL, Latkin C, Mehta SH. Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore. *J Subst Abuse Treat*. 2019;100:45-51.
 23. Sharfstein J and **Olsen Y**. Making Amends for the Opioid Epidemic. *JAMA*. 2019;321(15):1446-1447.
 24. Sharfstein J and **Olsen Y**. Lessons Learned from the Opioid Epidemic. *JAMA*. 2019. Published online August 5, 2019. doi:10.1001/jama.2019.9794
 25. Pytell JD, Sharfstein JM, Olsen Y. Facilitating Methadone Use in Hospitals and Skilled Nursing Facilities. *JAMA Intern Med*. 2020 Jan 1;180(1):7-8.
 26. Sharfstein JM, **Olsen Y**. How Not to Spend an Opioid Settlement. *JAMA*. 2020;323(11):1031-1032.
 27. Felix C, Sharfstein JM, **Olsen Y**. Help is on the Way: Medicare Coverage of Opioid Treatment Programs. *J Am Geriatr Soc*. 2020;68(3):637-640.
 28. Sharfstein JM, **Olsen Y**. The Role of Evidence in the US Response to the Opioid Crisis. *Epidemiol Rev*. 2020 Jan 31;42(1):167-170.
 29. **Olsen Y**, Fitzgerald RM, Wakeman SE. Overcoming Barriers to Treatment of Opioid Use Disorder. *JAMA*. 2021 Mar 23;325(12):1149-1150.
 30. **Olsen Y**. What Is Addiction? History, Terminology, and Core Concepts. *Med Clin North Am*. 2022 Jan;106(1):1-12.
 31. Selitsky L, Racha S, Rastegar D, **Olsen Y**. Infective endocarditis in people who inject drugs: A scoping review of clinical guidelines. *J Hosp Med*. 2023 Feb;18(2):169-176. doi: 10.1002/jhm.12996. Epub 2022 Nov 9.
 32. Jones CM, **Olsen Y**, Ali MM, Sherry TB, Mcaninch J, Creedon T, Juliana P, Jacobus-Kantor L, Baillieu R, Diallo MM, Thomas A, Gandotra N, Sokolowska M, Ling S, Compton W. Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines. *JAMA Health Forum*. 2023 Jul 7;4(7):e231982.
 33. Pericot-Valverde I, Lopes SS, Nahvi S, Thrasher JF, Karasz A, Taylor LE, Mehta SH, Lum PJ, Tsui JI, Page K, Feinberg J, Kim AY, Norton BL, Arnsten JH, Fernandez-Artamendi S, Heo M, Litwin A; **HERO Research Group**. Reduction in Depressive Symptoms in People who Inject Drugs who Are Cured of Hepatitis C

- Virus Infection: The HERO Study. *Open Forum Infect Dis.* 2023 Oct 5;10(11):ofad498.
34. Heo M, Norton BL, Pericot-Valverde I, Mehta SH, Tsui JI, Taylor LE, Lum PJ, Feinberg J, Kim AY, Arnsten JH, Sprecht-Walsh S, Page K, Murray-Krezan C, Anderson J, Litwin AH; **HERO Study Group**. Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study. *J Hepatol.* 2024 May;80(5):702-713.
 35. Dowell D, Brown S, Gyawali S, Hoenig J, Ko J, Mikosz C, Ussery E, Baldwin G, Jones CM, **Olsen Y**, Tomoyasu N, Han B, Compton WM, Volkow ND. Treatment for Opioid Use Disorder: Population Estimates - United States, 2022. *MMWR Morb Mortal Wkly Rep.* 2024 Jun 27;73(25):567-574.
 36. Litwin AH, Tsui JI, Heo M, Mehta SH, Taylor LE, Lum PJ, Feinberg J, Kim AY, Norton BL, Pericot-Valverde I, Arnsten J, Meissner P, Karasz A, McKee MD, Ward JW, Johnson N, Agyemang L, Stein ES, Thomas A, Borsuk C, Blalock KL, Wilkinson S, Wagner K, Carty J, Murray-Krezan C, Anderson J, Jacobsohn V, Luetkemeyer AF, Falade-Nwulia O, Groome M, Davies S, Costello K, Page K; **HERO Study Group**. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study. *JAMA Netw Open.* 2024 Aug 1;7(8):e2430024.
 37. Han B, Jones CM, Volkow ND, Rikard SM, Dowell D, Einstein EB, Guy GP, Tomoyasu N, Ko J, Baldwin G, **Olsen Y**, Compton WM. Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years. *JAMA Psychiatry.* 2025 Jun1;82(6):572-581.
 38. Baillieu R, Maring J, Olsen Y. Health Care Service Presence, Social Vulnerability, and Opioid Overdose Rate Acceleration: A United States, County-level Analysis, 2020-2022. *J Addict Med.* 2025 Oct 20. doi: 10.1097/ADM.0000000000001602. Online ahead of print.
 39. Guy GP Jr, Jones CM, Rikard SM, Zhang K, **Olsen Y**. Prescriber-Level Changes in Buprenorphine Dispensing in the USA Before and After Federal Policy Changes Aimed at Increasing Prescribing. *J Gen Intern Med.* 2025 Dec;40(16):4090-4093.
 40. **Olsen Y**, Brunner E, Ogbonna C, Boyle MP. Benzodiazepine Tapering: A Marathon, Not a Sprint. *J Addict Med.* 2026 Jan 20. doi: 10.1097/ADM.0000000000001657. Online ahead of print.

SELECTED OTHER PUBLICATIONS

1. **Olsen Y**, Daumit G. Opioid Prescribing for Chronic Non-malignant Pain in Primary Care: Challenges and Solutions. *Advances in Psychosomatic Medicine* 2004; 25:138-150.

2. **Olsen Y**, Gisriel E, Abraham M, Preston M, Bass EB. Increasing Buprenorphine Certification Among Office-Based Physicians in Maryland. *J Gen Int Med* 2005;20(S1):47.
3. **Olsen Y**, Alford DP. Chronic Pain Management in Patients with Substance Use Disorders. *Advanced Studies in Medicine* 2006;6(3):537-549.
4. **Olsen Y**. Chapter 72: Substance Abuse. In: Miller R, Sisson S, and Ashar B, (eds.). *The Johns Hopkins Internal Medicine Board Review 2008-2009*. Elsevier Science 2007; U.S.
5. McCaul ME, Wand G, **Olsen Y**. Alcohol and drug dependence. In: Warrell DA, Cox TA, Firth JD eds. *Oxford Textbook of Medicine*. 5th edition. Oxford, UK: Oxford University Press; 2010: 26.7.1.
6. Fields JB, Haning W, III, **Olsen Y**, Wilford BB. Chapter 19. Opioid Pharmacotherapies for Substance Use Disorder and Addiction. In: Robeck IR, Malinoff HL, Pohl MI, Waller RC, Weaver MF, Weiner MA, Haning WF, III, (eds). *The American Society of Addiction Medicine Handbook on Pain and Addiction*. New York, NY: Oxford University Press; 2018: pg. 221-242.
7. **Olsen Y**, and Sharfstein J. *The Opioid Epidemic: What Everyone Needs to Know*. Oxford University Press, New York, NY. 2019
8. **Olsen Y**, Alvanzo AH, Pytell JD. Chapter 7. Overview: Barriers and Advantages of Utilization of FDA-Approved Medications for Substance Use Disorders. In: Moeller FG, Terplan M, (eds). *Primer on Substance Use Disorders*. New York, NY: Oxford University Press, 2021: pg. 121-138.
9. **Olsen Y**, Mason A. Chapter 12: Bringing Primary Care to Opioid Treatment Programs. In: Rich, JD, Wakeman, SE, (eds). *Treating Opioid Use Disorder in General Medical Settings*. Springer Nature Switzerland AG., Cham, Switzerland. 2021: pg. 173-188.

INVITED TALKS AND PANELS

Substance Use Disorders and the Federal Landscape. Louisiana Association of Substance Abuse Counselors and Trainers (LASACT) Annual Conference, July 28, 2025.

The Regulatory Situation for Treatment of Opioid Use Disorder with Methadone: Where Are We?, Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws - A Workshop, The National Academies of Science, Engineering, and Medicine, March, 2022

The Opioid Epidemic, May 2021, NCSBN Discipline Case Management Conference, National Council of State Boards of Nursing, 2021 Virtual Conference

Strengthening Coordination Across the Social Safety Net for Patients with Addiction, Supporting People with Addiction During COVID-19 virtual webinar series, The National Academy of Medicine and the American Society of Addiction Medicine, June 2020

Opioid Crisis - Where Are We, What's Next?, October 2020, Virtual ACE/Allscripts Client Experience 2020 Conference

Applying Science to Clinical Care - What It Really Means to Treat Addiction as a Chronic Illness, December 2019, 5th Annual Penn State Addiction Symposium, Hershey, PA

Stemming the Tide: Hospital Improvements Impacting the Opioid Epidemic, July 2019, American Hospital Association 2019 Leadership Summit, San Diego, CA

Observations from an Urban Opioid Treatment Program, Breakout #4: Treating People Where They're At, June 2019, National Opioid Leadership Summit 2019, Public Health Institute, Sacramento, CA

Teaching Models for Reducing Bias and Stigma in the Context of Pain and Opioid Use Disorder, May 2019, Practical Strategies Breakout 3, Association of American Medical Colleges National Workshop to Advance Medical Education to Combat Opioid Misuse: Working Together Across the Continuum, Washington, DC

Utilization of Medications for Opioid Use Disorder Treatment in Criminal Justice Populations: A Community Provider Perspective, NIDA panel, May 2019, American Psychiatric Association Annual Meeting 2019, San Francisco, CA

Transitions in Opioid Use Disorder: A Role for Primary Care, October 2018, Mid-Atlantic Permanente Medical Group's 4th Annual Pain Summit, Bethesda, MD

Models of Opioid Addiction Treatment in Primary Care: Lessons Learned, October 2018, Wisconsin Coalition for Health Care Quality Assembly, Madison, WI

Opioid Addiction and Treatment: The Science, In Brief, October, 2017, Sheftell/Pollak Memorial Lecture, Stamford, CT

Opioid Addiction Treatment and Recovery Including a Medication: The Science and the Practice, September 2017, Science Over Stigma A Symposium on Treating the Opioid Epidemic in Southern Delaware, Central East Addiction Technology Transfer Center, Bridgeville, DE

Opioid Addiction Treatment and Recovery Including a Medication: The Science and the Practice, April 2017, Tuerk Conference, Baltimore, MD.

Opioids and Opioid Addiction: Practical Management Approaches, November 2016, The Opioid Crisis: Maryland Healthcare Reacts, The Maryland Patient Safety Center Conference, Ellicott City, MD

Integrated Care and the Health Home: Lessons Learned from a Maryland OTP, October 2016, Saving Lives: Access to Improved Health & Recovery 2016 Conference, American Association for the Treatment of Opioid Dependence, Baltimore, MD

Update on Opioid Addiction: From Policy to Practice, October 2016, Maryland Association of Chemical Dependency Nurses Annual Conference, Edgewood, MD

A Brief Primer on Medications for Opioid Use Disorder, September 2016, Saving Lives: Innovative Solutions to the Opioid Epidemic Conference, Hazeldon Betty Ford, Minneapolis, MN

Addiction, Treatment, and Recovery Parts 1 and 2, November 2015, NAMI Maryland 2015 Annual Conference, Towson, MD

Integrated Health Home Services in an Opioid Treatment Program, October 2014, Addiction Health Services Research Annual Conference, Boston, MA

The Disease of Addiction: Substance Abuse and Mental Illness and Co-Occurring Disorders, October 2012, Meritus Health Systems Seminar: Emerging Trends in the Treatment of Depression and Addiction, Hagerstown, MD

Integrated Care for People with Substance Use Disorders (SUDs), September 2012, University of Maryland Law School Seminar, Baltimore, MD

Prescription Medications and Substance Use Disorders, September 2012, Maryland Office of Problem Solving Courts Conference, Annapolis, MD

Issues and Opportunities: Partnerships between Behavioral Health Specialty System and FQHCs, May 2011, Federally Qualified Health Center Summit on Behavioral Health and Primary Care Services Integration, Columbia, MD

Harford County Partnership: The HOPE Project, May 2009, Maryland Partners for Justice Conference, Baltimore, MD

An Integrated Model for Treatment of Individuals with Co-Occurring Issues: Recovery Oriented System of Care, May 2009, Baltimore County Department of Health Conference: The Stimulus Package: Mental Health, Substance Abuse, and HIV/AIDS, Hunt Valley, MD

Quality Services for Persons with Substance Abuse Disorders and Serious Medical Illness, April 2005, Symposium on Understanding and Treating Co-Occurring Disorders: Operationalizing the Concept of Quality, Johns Hopkins Hospital, Baltimore, MD

Treating the Opioid Dependent Patient: Who and How, June 2006, Symposium on Buprenorphine: How to Make Office-Based Treatment Work for You, Your Patients, and Your Practice, Center for a Health Maryland, Howard County Health Department, MD

Chronic Pain and Opioid Prescribing in Primary Care: Challenges and Solutions, May 2006, Patient Safety Panel: Pain Management, 100th Anniversary Conference, Oklahoma State Medical Association, Oklahoma City, OK.

Opioid Addiction Treatment: A New Approach, October 2004, Medical Grand Rounds, Johns Hopkins Hospital, Baltimore, MD

Do Patients with Depression and Problem Drinking Benefit from Chronic Care Models?,
June 2004, Complexities of Co-Occurring Disorders Conference,
NIDA/NIMH/NIAAA/AHRQ/SAMHSA

GRANTS AWARDED

1. Targeted Capacity Expansion-HIV Program: Substance Use Disorder Treatment for Racial/Ethnic Minority Populations at High Risk for HIV/AIDS, 2018-2023, Substance Abuse and Mental Health Services Administration, Project Consultant until September 2021.
2. Integrating Services for Patients with Co-occurring Mental Illness and Substance Abuse; Partnering with the Criminal Justice System for Optimal Outcomes, 2008-2011, The Maryland Community Health Resources Commission, Project Director.
3. Improving and Expanding Opioid Addiction Treatment Services: A Hospital-Based Buprenorphine Project, 2005-2006, The Abell Foundation and the France-Merrick Foundation, Principal Investigator.
4. Randomized Trial of HIV-Clinic-Based Buprenorphine vs. Referred Substance Abuse Care. 2004-2009, Health Resources and Service Administration, M400-209-2984, Co Investigator 15%, Principal Investigator Greg Lucas, MD, PhD.